Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Current Liabilities (2020 - 2025)

Foghorn Therapeutics has reported Total Current Liabilities over the past 6 years, most recently at $59.7 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $59.7 million for Q4 2025, down 10.82% from a year ago — trailing twelve months through Dec 2025 was $59.7 million (down 10.82% YoY), and the annual figure for FY2025 was $59.7 million, down 10.82%.
  • Total Current Liabilities for Q4 2025 was $59.7 million at Foghorn Therapeutics, down from $85.1 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for FHTX hit a ceiling of $85.1 million in Q3 2025 and a floor of $16.3 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $55.2 million (2022), compared with a mean of $52.5 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 195.39% in 2022 and later dropped 10.82% in 2025.
  • Foghorn Therapeutics' Total Current Liabilities stood at $48.7 million in 2021, then rose by 13.38% to $55.2 million in 2022, then increased by 5.85% to $58.4 million in 2023, then grew by 14.64% to $67.0 million in 2024, then decreased by 10.82% to $59.7 million in 2025.
  • The last three reported values for Total Current Liabilities were $59.7 million (Q4 2025), $85.1 million (Q3 2025), and $77.8 million (Q2 2025) per Business Quant data.